The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.

ABSTRACT:

Background

It is not well known to what extent effectiveness of treatment with immune checkpoint inhibitors in stage IV non-small-cell lung cancer (NSCLC) is influenced by weight loss and changes in body composition. Therefore, the goal of this study was to evaluate body composition changes in relation to early weight change and overall survival (OS) in stage IV NSCLC patients treated with second-line nivolumab.

Methods

All patients with stage IV NSCLC, who were treated with second-line nivolumab between June 2015 and December 2018 at Maastricht University Medical Center, were evaluated. Skeletal muscle mass (SMM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were assessed at the first lumbar level on computed tomography images obtained before initiat

SUBMITTER: Degens JHRJ 

PROVIDER: S-EPMC8200425 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature